Special Issue "Role and Significance of Vaccines Against Animal Brucellosis"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 November 2023 | Viewed by 2644

Special Issue Editor

Department of Bacteriology, Kimron Veterinary Institute, Bet Dagan, Israel (Retired)
Interests: controlling veterinary bacterial zoonoses; brucellosis

Special Issue Information

Dear Colleagues,

Brucellosis remains a formidable challenge, recognized by the WHO as one of the most significant occupational and public health zoonoses, globally, and is still endemic in large parts of the world. Historically, Brucella melitensis, B. abortus, and B. suis were first identified as human zoonotic agents, instigating research programs on their pathogenesis and taxonomic structure which associated them with natural host animals in which they cause abortion storms at the third trimester. The growing evidence regarding their zoonotic potential and association of these bacteria with domesticated animals led to developing the serological and bacteriological standards necessary to act as regulatory tools in activating national and international animal trading policies. Simultaneously, live attenuated strains were developed as superior animal vaccines in comparison to sub-unit and killed vaccines. However, these vaccines caused problems linked to differentiating infected from vaccinated animals (DIVA) as well as being zoonotic to users., which biased control programs. In recent years, scientists have focused on the identification and characterization of novel Brucella species and their phylogenetic backgrounds, shedding light on the diversion between “classical Brucella” and earlier precursor lineages during the evolution of the genus. To this end, new high-throughput molecular approaches have been added as scientific tools in the combat against the disease.

We are enthusiastic to open this Special Issue on brucellosis and other zoonotic diseases, with the aim of widening our knowledge on this important disease.

We thus invite submission of research and review articles in the field of brucellosis which could enlighten us on the following subjects: identification and characterization of novel Brucella strains, molecular and bacteriological typing approaches, diagnosis, epidemiology, laboratory works with clinical samples, and research and development of novel vaccines.

Dr. Menachem Banai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


The Development of Diagnostic and Vaccine Strategies for Early Detection and Control of Human Brucellosis, Particularly in Endemic Areas
Vaccines 2023, 11(3), 654; https://doi.org/10.3390/vaccines11030654 - 14 Mar 2023
Cited by 2 | Viewed by 2363
Brucellosis is considered one of the most serious zoonotic diseases worldwide. This disease affects both human and animal health, in addition to being one of the most widespread zoonotic illnesses in the Middle East and Northern Africa. Human brucellosis generally presents in a [...] Read more.
Brucellosis is considered one of the most serious zoonotic diseases worldwide. This disease affects both human and animal health, in addition to being one of the most widespread zoonotic illnesses in the Middle East and Northern Africa. Human brucellosis generally presents in a diverse and non-specific manner, making laboratory confirmation of the diagnosis critical to the patient’s recovery. A coordinated strategy for diagnosing and controlling brucellosis throughout the Middle East is required, as this disease cannot be known to occur without reliable microbiological, molecular, and epidemiological evidence. Consequently, the current review focuses on the current and emerging microbiological diagnostic tools for the early detection and control of human brucellosis. Laboratory assays such as culturing, serology, and molecular analysis can frequently be used to diagnose brucellosis. Although serological markers and nucleic acid amplification techniques are extremely sensitive, and extensive experience has been gained with these techniques in the laboratory diagnosis of brucellosis, a culture is still considered to be the “gold standard” due to the importance of this aspect of public health and clinical care. In endemic regions, however, serological tests remain the primary method of diagnosis due to their low cost, user-friendliness, and strong ability to provide a negative prediction, so they are commonly used. A nucleic acid amplification assay, which is highly sensitive, specific, and safe, is capable of enabling rapid disease diagnosis. Patients who have reportedly fully healed may continue to have positive molecular test results for a long time. Therefore, cultures and serological methods will continue to be the main tools for diagnosing and following up on human brucellosis for as long as no commercial tests or studies demonstrate adequate interlaboratory reproducibility. As there is no approved vaccine that prevents human brucellosis, vaccination-based control of animal brucellosis has become an important part of the management of human brucellosis. Over the past few decades, several studies have been conducted to develop Brucella vaccines, but the problem of controlling brucellosis in both humans and animals remains challenging. Therefore, this review also aims to present an updated overview of the different types of brucellosis vaccines that are currently available. Full article
(This article belongs to the Special Issue Role and Significance of Vaccines Against Animal Brucellosis)
Show Figures

Figure 1

Back to TopTop